Please login to the form below

Not currently logged in
Email:
Password:

Sepracor signs EU marketing deal with GSK

Sepracor signs an agreement to market its sleep drug Lunivia with GSK in the EU

US-headquartered drug development company Sepracor has signed an agreement to market its sleep drug Lunivia (eszopiclone) in the EU with UK-based pharmaceutical company, GlaxoSmithKline (GSK).

Lunivia is currently under market review in the region, but has been commercially available in the US as Lunesta since 2005 to treat insomnia. Per the agreement, the drug will be marketed by GSK everywhere, except the US, Canada, Japan and Mexico.

Sepracor will receive an initial payment of USD 20m from GSK and is entitled to USD 155m in license and milestone payments, as well as double-digit royalties which would escalate upon increased product sales, says the firm.

In FY06, US product sales were about USD 566.8m, while the EU sedative hypnotic market was estimated to be worth about USD 500m in 2006.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....

Infographics